aluates Reports

$ 0.0

Automative

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Research Report 2026

Published Date: 2026-01-23

Report Code: QYRE-Auto-3D18746

Global Live Biotherapeutic Products LBP and Microbiome CDMO Service Market Research Report 2024

BUY CHAPTERS

Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Research Report 2026

Code: QYRE-Auto-3D18746

Report

2026-01-23

Pages:120

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Lallemand Health Solutions

Wacker Chemie AG

List Biological Labs, Inc

NIZO

SGS Quay Pharmaceuticals

Assembly Biosciences, Inc.

Lonza

Vermicon

Biose Industrie

Recipharm (Arranta Bio)

Bacthera (Novonesis+Lonza)

Smaltis

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size

The global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market was valued at US$ 223 million in 2025 and is anticipated to reach US$ 760 million by 2032, at a CAGR of 19.5% from 2026 to 2032.

Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market

Live Biotherapeutic Products (LBPs) are biotherapeutic products based on live microorganisms that are intended to treat or prevent disease by modulating the microbiome. These products are usually prepared from specific strains of microorganisms that have potential therapeutic effects, such as improving gut health, boosting the immune system, or reducing inflammation.The rising importance of the potential advantages of live biotherapeutic products and microbiome-based therapeutics in treating a variety of diseases, including inflammatory bowel disease, cancer, and neurological disorders, among patients and healthcare providers is the prime factor that propels market growth.CDMOs specializing in these fields have the expertise and infrastructure to support developing and manufacturing these complex therapies, which require specialized equipment and facilities. As a result, pharmaceutical and biotech companies can outsource their production to CDMOs, allowing them to focus on research and development.

The North American market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The global market for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service in Digestive System Diseases is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.

Major global companies of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service include Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Live Biotherapeutic Products (LBP) and Microbiome CDMO Service. The Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Live Biotherapeutic Products (LBP) and Microbiome CDMO Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Report

Report Metric	Details
Report Name	Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market
Accounted market size in 2025	US$ 223 million
Forecasted market size in 2032	US$ 760 million
CAGR	19.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Solid Dosage Form Liquid Dosage Form
Segment by Application	Digestive System Diseases Immune System Diseases Metabolic Diseases Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, Lonza, vermicon AG
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Live Biotherapeutic Products (LBP) and Microbiome CDMO Service companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market growing?

Ans: The Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market witnessing a CAGR of 19.5% during the forecast period 2026-2032.

What is the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market size in 2032?

Ans: The Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market size in 2032 will be US$ 760 million.

Who are the main players in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market report?

Ans: The main players in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market are Lallemand Health Solutions, Wacker Chemie AG, Biose Industrie, List Biological Labs, Inc., NIZO, SGS (Quay Pharmaceuticals), Assembly Biosciences, Inc., Recipharm (Arranta Bio), Bacthera (Novonesis+Lonza), Smaltis, Lonza, vermicon AG

What are the Application segmentation covered in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market report?

Ans: The Applications covered in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market report are Digestive System Diseases, Immune System Diseases, Metabolic Diseases, Other

What are the Type segmentation covered in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market report?

Ans: The Types covered in the Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market report are Solid Dosage Form, Liquid Dosage Form

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Solid Dosage Form

1.2.3 Liquid Dosage Form

1.3 Market by Application

1.3.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Digestive System Diseases

1.3.3 Immune System Diseases

1.3.4 Metabolic Diseases

1.3.5 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Perspective (2021–2032)

2.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Growth Trends by Region

2.2.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Region (2021–2026)

2.2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Region (2027–2032)

2.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Dynamics

2.3.1 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Industry Trends

2.3.2 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers

2.3.3 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Challenges

2.3.4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players by Revenue

3.1.1 Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players by Revenue (2021–2026)

3.1.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Players (2021–2026)

3.2 Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue

3.4 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Concentration Ratio

3.4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue in 2025

3.5 Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Head Offices and Areas Served

3.6 Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, Products and Applications

3.7 Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Breakdown Data by Type

4.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Type (2021–2026)

4.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Type (2027–2032)

5 Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Breakdown Data by Application

5.1 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Historic Market Size by Application (2021–2026)

5.2 Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021–2032)

6.2 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021–2026)

6.4 North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021–2032)

7.2 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021–2026)

7.4 Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021–2032)

8.2 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2021–2026)

8.4 Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021–2032)

9.2 Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021–2026)

9.4 Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (2021–2032)

10.2 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2021–2026)

10.4 Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Lallemand Health Solutions

11.1.1 Lallemand Health Solutions Company Details

11.1.2 Lallemand Health Solutions Business Overview

11.1.3 Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.1.4 Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.1.5 Lallemand Health Solutions Recent Development

11.2 Wacker Chemie AG

11.2.1 Wacker Chemie AG Company Details

11.2.2 Wacker Chemie AG Business Overview

11.2.3 Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.2.4 Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.2.5 Wacker Chemie AG Recent Development

11.3 Biose Industrie

11.3.1 Biose Industrie Company Details

11.3.2 Biose Industrie Business Overview

11.3.3 Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.3.4 Biose Industrie Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.3.5 Biose Industrie Recent Development

11.4 List Biological Labs, Inc.

11.4.1 List Biological Labs, Inc. Company Details

11.4.2 List Biological Labs, Inc. Business Overview

11.4.3 List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.4.4 List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.4.5 List Biological Labs, Inc. Recent Development

11.5 NIZO

11.5.1 NIZO Company Details

11.5.2 NIZO Business Overview

11.5.3 NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.5.4 NIZO Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.5.5 NIZO Recent Development

11.6 SGS (Quay Pharmaceuticals)

11.6.1 SGS (Quay Pharmaceuticals) Company Details

11.6.2 SGS (Quay Pharmaceuticals) Business Overview

11.6.3 SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.6.4 SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.6.5 SGS (Quay Pharmaceuticals) Recent Development

11.7 Assembly Biosciences, Inc.

11.7.1 Assembly Biosciences, Inc. Company Details

11.7.2 Assembly Biosciences, Inc. Business Overview

11.7.3 Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.7.4 Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.7.5 Assembly Biosciences, Inc. Recent Development

11.8 Recipharm (Arranta Bio)

11.8.1 Recipharm (Arranta Bio) Company Details

11.8.2 Recipharm (Arranta Bio) Business Overview

11.8.3 Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.8.4 Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.8.5 Recipharm (Arranta Bio) Recent Development

11.9 Bacthera (Novonesis+Lonza)

11.9.1 Bacthera (Novonesis+Lonza) Company Details

11.9.2 Bacthera (Novonesis+Lonza) Business Overview

11.9.3 Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.9.4 Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.9.5 Bacthera (Novonesis+Lonza) Recent Development

11.10 Smaltis

11.10.1 Smaltis Company Details

11.10.2 Smaltis Business Overview

11.10.3 Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.10.4 Smaltis Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.10.5 Smaltis Recent Development

11.11 Lonza

11.11.1 Lonza Company Details

11.11.2 Lonza Business Overview

11.11.3 Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.11.4 Lonza Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.11.5 Lonza Recent Development

11.12 vermicon AG

11.12.1 vermicon AG Company Details

11.12.2 vermicon AG Business Overview

11.12.3 vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Introduction

11.12.4 vermicon AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

11.12.5 vermicon AG Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Lallemand Health Solutions

Wacker Chemie AG

List Biological Labs, Inc

NIZO

SGS Quay Pharmaceuticals

Assembly Biosciences, Inc.

Lonza

Vermicon

Biose Industrie

Recipharm (Arranta Bio)

Bacthera (Novonesis+Lonza)

Smaltis

List of Tables

Table 1. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Solid Dosage Form

Table 3. Key Players of Liquid Dosage Form

Table 4. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 5. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (US$ Million), 2021–2026

Table 7. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2021–2026)

Table 8. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Region (US$ Million), 2027–2032

Table 9. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2027–2032)

Table 10. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Trends

Table 11. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Drivers

Table 12. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Challenges

Table 13. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Restraints

Table 14. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue by Players (US$ Million), 2021–2026

Table 15. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Players (2021–2026)

Table 16. Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Players by Tier (Tier 1, Tier 2, and Tier 3), based on Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue, 2025

Table 17. Ranking of Global Top Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Companies by Revenue (US$ Million) in 2025

Table 18. Global 5 Largest Players Market Share by Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue (CR5 and HHI), 2021–2026

Table 19. Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, Headquarters and Area Served

Table 20. Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, Products and Applications

Table 21. Global Key Players of Live Biotherapeutic Products (LBP) and Microbiome CDMO Service, Date of General Availability (GA)

Table 22. Mergers and Acquisitions, Expansion Plans

Table 23. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Type (US$ Million), 2021–2026

Table 24. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2021–2026)

Table 25. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Type (US$ Million), 2027–2032

Table 26. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Type (2027–2032)

Table 27. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (US$ Million), 2021–2026

Table 28. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2021–2026)

Table 29. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Forecasted Market Size by Application (US$ Million), 2027–2032

Table 30. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue Market Share by Application (2027–2032)

Table 31. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 32. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 33. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 34. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 35. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 36. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 37. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 38. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (US$ Million), 2021–2026

Table 39. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Region (US$ Million), 2027–2032

Table 40. Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 41. Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 42. Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 43. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 44. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2021–2026

Table 45. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Country (US$ Million), 2027–2032

Table 46. Lallemand Health Solutions Company Details

Table 47. Lallemand Health Solutions Business Overview

Table 48. Lallemand Health Solutions Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 49. Lallemand Health Solutions Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 50. Lallemand Health Solutions Recent Development

Table 51. Wacker Chemie AG Company Details

Table 52. Wacker Chemie AG Business Overview

Table 53. Wacker Chemie AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 54. Wacker Chemie AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 55. Wacker Chemie AG Recent Development

Table 56. Biose Industrie Company Details

Table 57. Biose Industrie Business Overview

Table 58. Biose Industrie Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 59. Biose Industrie Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 60. Biose Industrie Recent Development

Table 61. List Biological Labs, Inc. Company Details

Table 62. List Biological Labs, Inc. Business Overview

Table 63. List Biological Labs, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 64. List Biological Labs, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 65. List Biological Labs, Inc. Recent Development

Table 66. NIZO Company Details

Table 67. NIZO Business Overview

Table 68. NIZO Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 69. NIZO Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 70. NIZO Recent Development

Table 71. SGS (Quay Pharmaceuticals) Company Details

Table 72. SGS (Quay Pharmaceuticals) Business Overview

Table 73. SGS (Quay Pharmaceuticals) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 74. SGS (Quay Pharmaceuticals) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 75. SGS (Quay Pharmaceuticals) Recent Development

Table 76. Assembly Biosciences, Inc. Company Details

Table 77. Assembly Biosciences, Inc. Business Overview

Table 78. Assembly Biosciences, Inc. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 79. Assembly Biosciences, Inc. Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 80. Assembly Biosciences, Inc. Recent Development

Table 81. Recipharm (Arranta Bio) Company Details

Table 82. Recipharm (Arranta Bio) Business Overview

Table 83. Recipharm (Arranta Bio) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 84. Recipharm (Arranta Bio) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 85. Recipharm (Arranta Bio) Recent Development

Table 86. Bacthera (Novonesis+Lonza) Company Details

Table 87. Bacthera (Novonesis+Lonza) Business Overview

Table 88. Bacthera (Novonesis+Lonza) Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 89. Bacthera (Novonesis+Lonza) Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 90. Bacthera (Novonesis+Lonza) Recent Development

Table 91. Smaltis Company Details

Table 92. Smaltis Business Overview

Table 93. Smaltis Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 94. Smaltis Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 95. Smaltis Recent Development

Table 96. Lonza Company Details

Table 97. Lonza Business Overview

Table 98. Lonza Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 99. Lonza Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 100. Lonza Recent Development

Table 101. vermicon AG Company Details

Table 102. vermicon AG Business Overview

Table 103. vermicon AG Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Product

Table 104. vermicon AG Revenue in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (US$ Million), 2021–2026

Table 105. vermicon AG Recent Development

Table 106. Research Programs/Design for This Report

Table 107. Key Data Information from Secondary Sources

Table 108. Key Data Information from Primary Sources

Table 109. Authors List of This Report

List of Figures

Figure 1. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Picture

Figure 2. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Type: 2025 vs 2032

Figure 4. Solid Dosage Form Features

Figure 5. Liquid Dosage Form Features

Figure 6. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size by Application (US$ Million), 2021–2032

Figure 7. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Application: 2025 vs 2032

Figure 8. Digestive System Diseases Case Studies

Figure 9. Immune System Diseases Case Studies

Figure 10. Metabolic Diseases Case Studies

Figure 11. Other Case Studies

Figure 12. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Report Years Considered

Figure 13. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region: 2025 vs 2032

Figure 16. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Players in 2025

Figure 17. Global Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Revenue in 2025

Figure 19. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021–2032)

Figure 21. United States Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021–2032)

Figure 25. Germany Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Region (2021–2032)

Figure 33. China Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021–2032)

Figure 41. Mexico Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Share by Country (2021–2032)

Figure 45. Israel Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Lallemand Health Solutions Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 49. Wacker Chemie AG Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 50. Biose Industrie Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 51. List Biological Labs, Inc. Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 52. NIZO Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 53. SGS (Quay Pharmaceuticals) Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 54. Assembly Biosciences, Inc. Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 55. Recipharm (Arranta Bio) Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 56. Bacthera (Novonesis+Lonza) Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 57. Smaltis Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 58. Lonza Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 59. vermicon AG Revenue Growth Rate in Live Biotherapeutic Products (LBP) and Microbiome CDMO Service Business (2021–2026)

Figure 60. Bottom-up and Top-down Approaches for This Report

Figure 61. Data Triangulation

Figure 62. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Biological Drug CDMO Market Research Report 2024

Global Microbiome CDMO Market Research Report 2024

Global Biopharmaceutical and Bio CDMO Market Research Report 2024

Global Biopharmaceutical CDMO Service Market Research Report 2024

Global Biopharmaceutical CDMO Market Research Report 2025

Biologics CDMO Market

Global Microbial Fermentation CDMO Services Market Research Report 2024

Global Postbiotics CDMO Service Market Research Report 2024

Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030

Live Biotherapeutic Products Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Cell and Gene Therapy CDMO Services Market Research Report 2024

Global Cell Therapy CDMO Services Market Research Report 2025

Global Microbial Therapeutic Products Market Research Report 2024

Global Biologics Clinical Manufacturing CDMO Service Market Research Report 2024

Global Live Biotherapeutic Products LBP CDMO Service Market Research Report 2024

Global Biologic Medical Product Market Research Report 2025

Therapeutic Products from Microbe Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Viral Vector Manufacturing CDMO Services Market Research Report 2024

Global Probiotics CDMO Service Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions